Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 8:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–22 of 22 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Remediation of Impaired Self-Regulation in Patients With Mild TBI

NCT02260570
Conditions
Mild Traumatic Brain Injury
Interventions
Tolcapone, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 50 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2021
U.S. locations
1
States / cities
Sacramento, California
Completed Not applicable Interventional Results available

Treatment for Nicotine Addiction in Women

NCT02448654
Conditions
Nicotine Dependence
Interventions
Tolcapone, Sugar Pill
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
West Haven, Connecticut
Conditions
Neuroblastoma
Interventions
Tolcapone, Oxaliplatin
Drug
Lead sponsor
Giselle Sholler
Other
Eligibility
0 Years to 21 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
9
States / cities
Little Rock, Arkansas • San Diego, California • Hartford, Connecticut + 6 more
Completed Phase 2Phase 3 Interventional Results available

Tolcapone in Obsessive Compulsive Disorder

NCT03348930
Conditions
Obsessive-Compulsive Disorder
Interventions
Tolcapone 200 MG
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Obsessive-Compulsive Disorder, OCD
Interventions
Tolcapone, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Alcohol Use Disorder
Interventions
Tolcapone, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
21 Years to 40 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Charleston, South Carolina
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effects of Tolcapone on Decision Making and Alcohol Intake in Alcohol Users

NCT02740582
Conditions
Alcohol Abuse, Impulsive Behavior
Interventions
Tolcapone, Placebo
Drug
Lead sponsor
Jennifer Mitchell
Other
Eligibility
21 Years to 40 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
2
States / cities
Berkeley, California • San Francisco, California
Completed Phase 2 Interventional Results available

Effects of Tolcapone on Frontotemporal Dementia

NCT00604591
Conditions
Frontotemporal Lobar Degeneration
Interventions
Tolcapone, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
40 Years to 85 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
New York, New York
Completed Early Phase 1 Interventional Accepts healthy volunteers

Dopaminergic Mechanisms Underlying Human Social Behavior

NCT04205994
Conditions
Decision Making, Executive Function, Dopamine
Interventions
Tolcapone 200 MG, Functional Magnetic Resonance Imaging (fMRI)
Drug · Other
Lead sponsor
University of California, Berkeley
Other
Eligibility
18 Years to 40 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Berkeley, California
Conditions
Transthyretin Amyloidosis, Amyloidosis, Leptomeningeal, Transthyretin-Related
Interventions
Tolcapone
Drug
Lead sponsor
Boston University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Cocaine-Related Disorders
Interventions
Tolcapone
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
Los Angeles, California
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Clinical Trial of Tolcapone for Cognition in Schizophrenia

NCT00044083
Conditions
Schizophrenia
Interventions
Placebo, Tolcapone
Other · Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 50 Years
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Phase 2 Interventional Results available

Neural Substrates in Nicotine Withdrawal

NCT01001520
Conditions
Tobacco Use Disorder
Interventions
Tolcapone, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed Phase 2 Interventional Results available

Tolcapone Treatment of Pathological Gambling

NCT00927563
Conditions
Pathological Gambling
Interventions
Tolcapone
Drug
Lead sponsor
University of Chicago
Other
Eligibility
21 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Minneapolis, Minnesota
Completed Phase 1 Interventional Accepts healthy volunteers

Microbiome Derived Metabolism and Pharmacokinetics

NCT05065671
Conditions
Microbial Colonization
Interventions
Tolcapone 100 MG, Duloxetine 20 MG
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Somerville, New Jersey
Conditions
Brain Injuries, Brain Injuries, Traumatic, Brain Injury, Chronic
Interventions
Tolcapone 200 MG, Placebo
Drug · Other
Lead sponsor
Sheppard Pratt Health System
Other
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Towson, Maryland
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Gait Analysis in Neurological Disease

NCT02994719
Conditions
Parkinson's Disease, Parkinsonian Disorders, Atypical Parkinson Disease, Progressive Supranuclear Palsy, Multiple System Atrophy, Corticobasal Degeneration, Gait, Frontal, Huntington Disease, Ataxia, Spinocerebellar
Interventions
Anti-Parkinson medication, Deep Brain Stimulation
Drug · Device
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Phase 2 Interventional Results available

Pilot Study of Tolcapone in Smokers

NCT01202955
Conditions
Nicotine Dependence
Interventions
Tolcapone, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Alcohol Use Disorder, Attention Deficit Hyperactivity Disorder
Interventions
Tolcapone, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Addiction
Interventions
Tolcapone, Placebo, Bromocriptine
Drug
Lead sponsor
University of California, Berkeley
Other
Eligibility
18 Years to 50 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
2
States / cities
Berkeley, California • San Francisco, California
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Study of Neural Circuit Responses to Catechol-O-methyl Transferase (COMT) Inhibitors

NCT01158950
Conditions
Impulsive Behavior
Interventions
Tolcapone, Placebo
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 50 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2018
U.S. locations
2
States / cities
Berkeley, California • Emeryville, California
Conditions
Brain Injuries, Traumatic, Neurocognitive Disorders, Brain Injuries
Interventions
Tolcapone
Drug
Lead sponsor
Sheppard Pratt Health System
Other
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2015
U.S. locations
1
States / cities
Baltimore, Maryland